Tsikouras Panagiotis, Gkaitatzi Foteini, Gerede Aggeliki, Anthoulaki Xanthoula, Bothou Anastasia, Chalkidou Anna, Michalopoulos Spyridon, Tsirkas Ioannis, Gyroglou Selma, Peitsidis Panagiotis, Nikolettos Konstantinos, Alexiou Alexios, Dragoutsos George, Sachnova Natalia, Chloropoulou Pelagia, Zervoudis Stefanos, Iatrakis George, Rath Werner, Trypsiannis Grigorios, Nikolettos Nikolaos, Souftas Vasileios
Department of Obstetrics and Gynecology, Democritus University of Thrace, 68100 Alexandropoulis, Greece.
Rea Maternity Hospital, University of West Attica, 17564 Athens, Greece.
J Pers Med. 2022 Dec 1;12(12):1990. doi: 10.3390/jpm12121990.
Fibroids cause significant morbidity and are the most common indication for hysterectomies worldwide, delimiting a major public health problem. Uterine artery embolization (UAE) is an alternative therapy to surgical treatment of symptomatic fibroids; it has satisfactory long-time results and is no longer considered investigational for the treatment of symptomatic fibroids. This study was undertaken to evaluate changes in fibroid specific symptom severity and health-related quality of life (HRQOL) after UAE and to optimize the assessment of safety and outcomes measures for participants who receive UAE to objective compare UAE and surgical alternatives for therapy of symptomatic fibroids. The analysis was based on questionnaires completed by 270 pre-menopausal females with a mean age of 42 years (range, 38-50 years) who underwent UAE for uterine leiomyomas and/or adenomyosis from November 2013 through December 2019. Only symptomatic women were selected whose symptoms were not improving with medication and who did not wish to have children. The primary outcome measure was a change in fibroid symptoms and HRQOL (health related quality of life) after UAE. Secondary outcomes included the decrease in uterine volume after UAE. Questionnaires were completed by 270 women (100%) at a mean of 12.1 months from UAE. The median follow-up period was two years. Uterine fibroid embolization led to a shrinkage at three months for the 90% of the participants. A reduction of bleeding symptoms, pain and bulk-related symptoms was observed in 89.7%, 88.9%, and 89.5% of the patients, respectively. In the long term, there was no significant difference in parameters assessed compared with the midterm follow-up findings. A total of 6 patients (2.3%) underwent fractional curettage an average of 32.1 months after intervention due to necrotic changes in submucosal fibroids. All participants continued to be satisfied with the intervention, and 240 patients (88.9%) answered that they would recommend uterine fibroid embolization to other patients. Women who undergo UAE have a significant decrease in symptom severity and increase in HRQOL which is associated with high levels of satisfaction with the procedure (even when subsequent therapies are pursued).
子宫肌瘤会引发严重的发病率问题,是全球范围内子宫切除术最常见的指征,界定了一个重大的公共卫生问题。子宫动脉栓塞术(UAE)是有症状子宫肌瘤手术治疗的替代疗法;它具有令人满意的长期效果,不再被视为治疗有症状子宫肌瘤的试验性方法。本研究旨在评估UAE后肌瘤特异性症状严重程度和健康相关生活质量(HRQOL)的变化,并优化对接受UAE参与者的安全性和结局指标的评估,以便客观比较UAE与有症状子宫肌瘤治疗的手术替代方法。该分析基于270名绝经前女性填写的问卷,这些女性平均年龄42岁(范围38 - 50岁),在2013年11月至2019年12月期间因子宫平滑肌瘤和/或子宫腺肌病接受了UAE。仅选择症状性女性,其症状药物治疗无改善且不希望生育。主要结局指标是UAE后肌瘤症状和HRQOL的变化。次要结局包括UAE后子宫体积的减小。270名女性(100%)在距UAE平均12.1个月时完成了问卷。中位随访期为两年。90%的参与者在三个月时子宫肌瘤栓塞导致肌瘤缩小。分别在89.7%、88.9%和89.5%的患者中观察到出血症状、疼痛和与肿块相关症状的减轻。从长期来看,与中期随访结果相比,评估的参数没有显著差异。共有6名患者(2.3%)在干预后平均32.1个月因黏膜下肌瘤坏死变化接受了分段刮宫术。所有参与者对该干预仍感到满意,240名患者(88.9%)回答他们会向其他患者推荐子宫肌瘤栓塞术。接受UAE的女性症状严重程度显著降低,HRQOL提高,这与对该手术的高度满意度相关(即使后续进行了其他治疗)。